Table 1.
Demographic and health-related characteristics of those with and without CSF in the NEAD study
| Characteristics | With CSF and cognitive testing
|
No CSF and/or cognitive testing
|
|||
|---|---|---|---|---|---|
| Mean (SD)/n (%) | n | Mean (SD)/n (%) | n | p value | |
| Age at baseline, years | 41.3 (5.4) | 31 | 40.5 (7.2) | 17 | 0.646 |
| Male | 21 (67.7%) | 31 | 13 (76.5%) | 17 | 0.386 |
| Race | |||||
| Caucasian | 4 (12.9%) | 31 | 3 (17.7%) | 17 | 0.801 |
| African American | 26 (83.9%) | 14 (82.4%) | |||
| Hispanic | 1 (3.2%) | 0 | |||
| Education, years | 12.1 (1.7) | 31 | 12.0 (1.6) | 17 | 0.802 |
| Any R2 Therapy | 25 (80.7%) | 31 | 8 (53.3%) | 17 | 0.082 |
| MSK | |||||
| 0 | 7 (22.6%) | 31 | 8 (53.3) | 15 | 0.224 |
| 0.5 | 5 (16.13%) | 2 (13.3%) | |||
| 1 | 12 (38.7%) | 2 (13.3%) | |||
| 2 | 6 (19.4%) | 3 (20.0%) | |||
| 3 | 1 (3.2%) | 0 | |||
| Beck Depression Inventory | 12.5 (8.9) | 31 | 13.4 (11.1) | 0.767 | |
| IADL score | 22.2 (2.3) | 31 | 23.5 (1.1) | 15 | 0.041 |
| UPDRS total score | 8.4 (8.1) | 30 | 4.5 (5.6) | 15 | 0.107 |
| Ever used drugs | 31 (100%) | 31 | 15 (100%) | 15 | 1.000 |
| Currently use drugs | 15 (48.4%) | 31 | 8 (53.3%) | 15 | 1.000 |
| Currently use alcohol | 10 (32.3%) | 31 | 4 (26.7%) | 15 | 1.000 |
| CD4 cell count | 154.1 (136.1) | 29 | 190.9 (181.0) | 16 | 0.445 |
| CD8 cell count | 755.0 (605.8) | 25 | 751.2 (417.3) | 13 | 0.984 |
| Using Antiretroviral therapy | 25 (80.7%) | 31 | 8 (53.3%) | 15 | 0.082 |
| Plasma HIV RNA (log10 copies/mL) | 3.8 (1.5) | 29 | 4.5 (1.0) | 13 | 0.143 |
| CSF HIV RNA (log10 copies/mL) | 2.7 (1.1) | 28 | |||
| Duration of HIV, years | 7.5 (4.5) | 31 | 7.3 (4.8) | 16 | 0.861 |
| Symptomatic DSP | 18 (58.1%) | 31 | 4 (28.6%) | 14 | 0.108 |
| Asymptomatic DSP | 10 (32.3%) | 31 | 9 (64.3%) | 14 | 0.057 |
Note. MSK = Memorial Sloan-Kettering (MSK); IADL = Instrumental Activities of Daily Living; UPDRS = Unified Parkinson’s Disease Rating Scale; DSP = Distal Sensory Polyneuropathy.